C4 Therapeutics, Inc. Operating Lease, Payments
C4 Therapeutics, Inc. (CCCC) reported Operating Lease, Payments of $4.67 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-08-11
- C4 Therapeutics, Inc. operating lease, payments for the quarter ending 2026-06-30 was $2.35M, a 2.81% decline year-over-year.
- C4 Therapeutics, Inc. operating lease, payments for the quarter ending 2026-03-31 was $2.32M, a 3.02% increase year-over-year.
- C4 Therapeutics, Inc. operating lease, payments for the quarter ending 2025-09-30 was $2.15M, a 3.12% decline year-over-year.
- C4 Therapeutics, Inc. operating lease, payments for the quarter ending 2025-06-30 was $2.42M, a 9.12% increase year-over-year.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month |
|---|---|---|---|
| 2026-06-30 | $2.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $4.67M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $2.32M 10-Q · filed 2026-05-12 | ||
| 2025-09-30 | $2.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $4.56M derived: sum of 2 quarters · filed 2026-08-11 | $6.81M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $2.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $4.67M 10-Q · filed 2026-08-11 | |
| 2025-03-31 | $2.25M 10-Q · filed 2026-05-12 | ||
| 2024-09-30 | $2.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $4.43M derived: sum of 2 quarters · filed 2025-11-06 | $6.61M 10-Q · filed 2025-11-06 |
| 2024-06-30 | $2.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $4.40M 10-Q · filed 2025-08-07 | |
| 2024-03-31 | $2.18M 10-Q · filed 2025-05-07 | ||
| 2023-09-30 | $2.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $4.30M derived: sum of 2 quarters · filed 2024-10-31 | $6.42M 10-Q · filed 2024-10-31 |
| 2023-06-30 | $2.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $4.27M 10-Q · filed 2024-08-01 | |
| 2023-03-31 | $2.12M 10-Q · filed 2024-05-08 | ||
| 2022-09-30 | $2.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $4.17M derived: sum of 2 quarters · filed 2023-11-01 | $5.08M 10-Q · filed 2023-11-01 |
| 2022-06-30 | $2.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $3.00M 10-Q · filed 2023-08-08 | |
| 2022-03-31 | $908.00K 10-Q · filed 2023-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |